Rivahib^®

Rivahib^® contains the active ingredient rivaroxaban.

Rivahib^® 2.5 mg film-coated tablets are used in adults:

• In confirmed acute coronary syndrome (a group of conditions that includes myocardial infarction and unstable angina, a severe form of chest pain) and in the presence of elevated cardiac‑specific laboratory markers from blood tests. Rivahib^® reduces the risk of another heart attack in adults and lowers the risk of death due to heart or vascular disease. Rivahib^® is not given on its own. The physician will additionally prescribe one of the following medicinal products:

– acetylsalicylic acid, or
– acetylsalicylic acid plus clopidogrel or ticlopidine.

• In patients with a high confirmed risk of blood clots due to coronary artery disease or symptomatic peripheral arterial occlusive disease. Rivahib^® reduces the risk of blood clots (atherothrombotic events) in adults. Rivahib^® is not given on its own. The physician will additionally prescribe acetylsalicylic acid. In some cases, when Rivahib^® is given after a procedure to reopen a narrowed or blocked leg artery to restore blood flow, the physician may also prescribe short‑term clopidogrel in addition to acetylsalicylic acid.

Rivahib® 10 mg hard capsules and film‑coated tablets are used in adults:

• to prevent the formation of blood clots in the veins after hip or knee replacement surgery. This medicinal product is prescribed because there is an increased risk of blood clot formation after an operation.
• to treat blood clots in the veins of the legs (deep vein thrombosis, DVT) and the blood vessels of the lungs (pulmonary embolism) as well as to prevent DVT and pulmonary embolism from recurring.

Rivahib^® 15 mg and 20 mg hard capsules and film-coated tablets are used in adults:

• to prevent stroke (blood clot in the brain) and other blood vessels in the body when patients suffer from a form of cardiac arrhythmia called non-valvular atrial fibrillation (not caused by heart valve disease).
• to treat blood clots in the veins of the legs (deep vein thrombosis, DVT) and the blood vessels of the lungs (pulmonary embolism) as well as to prevent DVT and pulmonary embolism from recurring.

Rivahib^® 15 mg and 20 mg hard capsules are used in children and adolescents under 18 years of age and weighing 30 kg or more:

• for the treatment of blood clots and prevention of recurrence of blood clots in the veins or blood vessels of the lungs after at least 5 days of initial treatment with injectable medicines for the treatment of blood clots.

Rivahib^® belongs to a group of medicines called antithrombotic agents. It works by inhibiting a blood clotting factor (factor Xa), thereby reducing the blood’s tendency to form blood clots.